Reading view
Interpretable Question Answering with Knowledge Graphs
Insights into the Unknown: Federated Data Diversity Analysis on Molecular Data
Integrating Transparent Models, LLMs, and Practitioner-in-the-Loop: A Case of Nonprofit Program Evaluation
The Right to Be Remembered: Preserving Maximally Truthful Digital Memory in the Age of AI
TinySQL: A Progressive Text-to-SQL Dataset for Mechanistic Interpretability Research
Quantum Natural Language Processing: A Comprehensive Review of Models, Methods, and Applications
LongCodeBench: Evaluating Coding LLMs at 1M Context Windows
With Limited Data for Multimodal Alignment, Let the STRUCTURE Guide You
ACT: Agentic Classification Tree
STAT+: Moderna says key study of its CMV vaccine, expected to be its next big win, failed
Moderna said Wednesday afternoon that its experimental vaccine for cytomegalovirus, a cause of disability in newborns, failed in a Phase 3 trial, a significant setback for a company already facing pressure from Wall Street and the federal government.
The CMV vaccine had been the company’s lead program prior to the Covid-19 pandemic. Leadership had repeatedly said it could bring in between $2 billion and $5 billion in peak annual sales. Analysts polled by Visible Alpha forecast peak sales of $1.6 billion for the product.
“It’s obviously disappointing,” said Stephen Hoge, Moderna’s president, in an interview.
Continue to STAT+ to read the full story…


© Ruby Wallau for STAT
STAT+: European oncology experts roll out guidance for use of large language models in clinical care
BERLIN — The leading professional organization for European oncologists has rolled out its first set of guidance on how its members should use large language models, a type of artificial intelligence, in cancer medicine.
“The oncology community cannot ignore the potential benefits which AI technology can provide to cancer patients,” the authors of the guidance wrote, while simultaneously acknowledging that there aren’t enough evaluations of the chatbots available to patients or tools available to doctors to address the risks associated with generative AI in medicine.
The guidance’s release — it was published last Saturday in the Annals of Oncology — coincided with the annual meeting for the European Society for Clinical Oncology in Berlin. The American Society of Clinical Oncology has issued its own set of principles for the responsible use of AI in cancer medicine, but has not released recommendations specific to large language models (LLMs).
Continue to STAT+ to read the full story…


© Adobe
Discovering state-of-the-art reinforcement learning algorithms
Nature, Published online: 22 October 2025; doi:10.1038/s41586-025-09761-x
Discovering state-of-the-art reinforcement learning algorithmsPancreatic cancer relies on opposing signalling pathways to drive its cellular diversity
Nature, Published online: 22 October 2025; doi:10.1038/d41586-025-03133-1
Communication between epithelial and mesenchymal cells in pancreatic cancer leads to a poor prognosis. The molecular basis for this signalling has now been revealed.Meflin is a druggable target using antibody-drug conjugates in progressive osteosarcoma
Oncogene, Published online: 21 October 2025; doi:10.1038/s41388-025-03605-8
Meflin is a druggable target using antibody-drug conjugates in progressive osteosarcomaQuantum cryptography and data protection for medical devices before and after they meet Q-Day
npj Digital Medicine, Published online: 21 October 2025; doi:10.1038/s41746-025-02082-3
Although still at a nascent state, quantum computing promises advances in healthcare, from drug discovery to personalised treatments. But it also threatens current cryptographic systems that protect medical data and infrastructure. The concept of “Q-Day” highlights risks such as “harvest now, decrypt later” attacks, with particular concerns for medical devices and sensitive applications in fields like femtech. Preparing for this future requires the rapid adoption of post-quantum cryptography, the coordination of time-phased and scalable “technology rollout” strategies, and revised regulatory frameworks to safeguard patient safety, privacy, and trust.Integrated epigenetic and genetic programming of primary human T cells
Nature Biotechnology, Published online: 21 October 2025; doi:10.1038/s41587-025-02856-w
Multiplexed editing in primary human T cells generates enhanced immune cell therapies.STAT+: Is a battle brewing between Abridge and OpenEvidence?
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.
Abridge vs. OpenEvidence, round one
New announcements from Abridge and OpenEvidence, two of the most prominent health tech startups to emerge in recent years, highlight how despite different initial offerings, many artificial intelligence companies in health care will just end up competing with each other for physician eyeballs.
On Monday morning, Abridge, best known for its AI scribe that helps doctors automate the writing of clinical notes, announced a new product that will surface “real-time insights, prompts, and pathways” from the widely-used medical resource UpToDate based on things said in a clinical conversation and that are written in the patient’s record.
Continue to STAT+ to read the full story…


© ADOBE, Alex Hogan/STAT
Effectiveness of a Digital Therapy on 6-Month Weight Loss in People With Obesity: The Digital Therapy to Promote Weight Loss in Patients With Obesity by Increasing Their Adherence to Treatment (DEMETRA) Randomized Clinical Trial
Comprehensive bioinformatics analysis of omics data to reveal molecular mechanisms and biomarkers in multiple cancers
In Silico Pharmacol. 2025 Oct 17;13(3):154. doi: 10.1007/s40203-025-00440-3. eCollection 2025.
ABSTRACT
Breast, ovarian, lung, cervical, and colorectal cancers are among the most prevalent malignancies affecting women worldwide. This study aimed to elucidate the common molecular mechanisms of tumorigenesis and identify potential biomarkers using an integrative bioinformatics and network-based approach. Integrative profiling of five microarray datasets identified 66 differentially expressed genes (DEGs) that are common across five cancer types. Gene ontology and KEGG pathway analyses of common DEGs were performed using the DAVID database. The cell cycle processes were the most enriched functions, and oocyte meiosis, oocyte maturation, the p53 signaling pathway, cancer pathways, and cellular senescence were the most important pathways identified. Protein-protein interaction (PPI) networks for the DEGs were constructed using the STRING database, and the resulting networks were visualized in Cytoscape. Through PPI network analysis, ten hub genes were identified, and subsequent survival analysis confirmed that CHEK1, DLGAP5, CCNB2, and CCNA2 are significantly associated with poor patient survivability, establishing them as common biomarkers across multiple cancer types. Subsequently, ten transcription factors (TFs) and ten post-transcriptional regulators were identified through the assessment of regulatory networks involving TFs-DEGs and miRNAs-DEGs. Finally, drug-gene association analysis from the GSCA library was used to anticipate drug-like compounds using the drug repurposing approach. Overall, this comprehensive investigation holds promise for future in vitro and in vivo studies, offering a molecular foundation for the diagnosis, prognosis, and treatment of malignant cancers.
SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40203-025-00440-3.
PMID:41113171 | PMC:PMC12534660 | DOI:10.1007/s40203-025-00440-3